Thinly traded nano cap Equillium (NASDAQ:EQ) rockets 207% premarket on increased volume in reaction to an announcement from partner Biocon Limited (OTC:BCNQY) that results from a clinical trial in India showed that itolizumab significantly reduced mortality in hospitalized COVID-19 patients.
The Drugs Controller General of India has granted restricted emergency use of itolizumab for the treatment of cytokine release syndrome (CRS) in COVID-19 patients with moderate-to-severe acute respiratory distress syndrome (ARDS).
Equillium is planning to conduct a global randomized study testing itolizumab in COVID-19 patients. An IND is next up.
Itolizumab is a monoclonal antibody that binds to an immune checkpoint receptor called CD6 that plays a key role in a wide range of immuno-inflammatory diseases.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.